                </a></li></ul></div><p><strong>Figure 2.  <span><sup>225</sup>Ac-E4G10 therapy inhibits the growth of LnCap prostate tumors.</span></strong></p><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1"></a><p>A, Flow cytometric analysis depicting the lack of E4G10 binding to LnCap cells; J591, mouse-anti prostate specific membrane antigen is the positive control. Mouse and rat isotype controls were also evaluated. B, Photographs of in situ (left) and excised tumor (right) in a representative dual control and <sup>225</sup>Ac-E4G10 treated animal. C, Tumor volume in various treatment groups at described time-points. D, Serum prostate specific antigen (PSA) levels in the three treatment groups at 22 days post-implantation with 5 million LnCap cells. E, Kaplan Meier curve showing enhancement of survival with <sup>225</sup>Ac-E4G10 treatment. Data in C, D are mean Â± S.E.M. <em>Scale bar</em>, 1 cm.</p>
